Andrew Chow
YOU?
Author Swipe
View article: 510 Dynamic tumor and immune response to neoadjuvant nivolumab with chemotherapy in diffuse pleural mesothelioma
510 Dynamic tumor and immune response to neoadjuvant nivolumab with chemotherapy in diffuse pleural mesothelioma Open
View article: Predictors of Biologic Drug Survival Time in Patients with Psoriatic Arthritis in a Community-Based Practice
Predictors of Biologic Drug Survival Time in Patients with Psoriatic Arthritis in a Community-Based Practice Open
Objectives First, to compare the duration of drug survival of biologic drugs used in the treatment of psoriatic arthritis in a community-based practice. Second, to assess the influence of sex, smoking status, HLA-B27 status, and concomitan…
View article: Retrospective Comparative Analysis of Diagnostic Tools for Giant Cell Arteritis
Retrospective Comparative Analysis of Diagnostic Tools for Giant Cell Arteritis Open
Objectives To assess the diagnostic performance of various giant cell arteritis (GCA) diagnostic tools including temporal artery biopsy (TAB), which is the current gold standard for GCA diagnosis, temporal artery ultrasound (US), presence …
View article: ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer Open
Patients with small-cell lung cancer (SCLC) have poor prognosis and typically experience only transient benefits from combined immune checkpoint blockade (ICB) and chemotherapy. Here, we show that inhibition of ataxia telangiectasia and ra…
View article: Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies
Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies Open
Chimeric antigen receptor T cells have dramatically improved the treatment of hematologic malignancies. T cell antigen receptor (TCR)-based cell therapies are yet to achieve comparable outcomes. Importantly, chimeric antigen receptors not …
View article: Role of CD38 in anti-tumor immunity of small cell lung cancer
Role of CD38 in anti-tumor immunity of small cell lung cancer Open
Introduction Immune checkpoint blockade (ICB) with or without chemotherapy has a very modest benefit in patients with small cell lung cancer (SCLC). SCLC tumors are characterized by high tumor mutation burden (TMB) and low PD-L1 expression…
View article: PRECISION-TBI: a study protocol for a vanguard prospective cohort study to enhance understanding and management of moderate to severe traumatic brain injury in Australia
PRECISION-TBI: a study protocol for a vanguard prospective cohort study to enhance understanding and management of moderate to severe traumatic brain injury in Australia Open
Introduction Traumatic brain injury (TBI) is a heterogeneous condition in terms of pathophysiology and clinical course. Outcomes from moderate to severe TBI (msTBI) remain poor despite concerted research efforts. The heterogeneity of clini…
View article: Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer Open
Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, …
View article: A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289
A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289 Open
View article: Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report
Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for ALK-Rearranged NSCLC—A Case Report Open
View article: 878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants
878 T cell immunotherapies recruit and activate neutrophils to eliminate tumor antigen escape variants Open
Background The combination of an ATR inhibitor ceralasertib and anti-PD-L1 antibody durvalumab is being tested in Phase III clinical trials in patients who have progressed on prior immunotherapy. Preclinical experiments were performed to b…
View article: A Unique Presentation of an Infected Renal Cyst: A Case Report and Literature Review
A Unique Presentation of an Infected Renal Cyst: A Case Report and Literature Review Open
Renal cysts are prevalent conditions and are often diagnosed incidentally. The infection of renal cysts is an uncommon presentation. It is even more rare in solitary simple cysts than in autosomal dominant polycystic kidney disease (ADPKD)…
View article: Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers
Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers Open
In lung and prostate adenocarcinomas, neuroendocrine (NE) transformation to an aggressive derivative resembling small cell lung cancer (SCLC) is associated with poor prognosis. We previously described dependency of SCLC on the nuclear tran…
View article: Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector
Identification of transcriptional programs using dense vector representations defined by mutual information with GeneVector Open
View article: Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation
Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation Open
View article: Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer Open
View article: Supplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation Open
Supplemental figures and figure legends.
View article: Supplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplementary Figures from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation Open
Supplemental figures and figure legends.
View article: Data from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Data from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation Open
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molec…
View article: Supplementary Tables from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplementary Tables from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation Open
Supplemental tables S1-S15
View article: Supplementary Tables from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Supplementary Tables from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation Open
Supplemental tables S1-S15
View article: Data from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation
Data from Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation Open
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molec…
View article: Data from <i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance
Data from <i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance Open
Purpose:MET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in MET exon 14–altered lung cancers, likely secondary to primary resistance. Mechanisms of primary resistance remain poorly characterized and compreh…
View article: Supplementary Data from <i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance
Supplementary Data from <i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance Open
Supplementary Figures S1-S6, Table S1-S3, and eMethods
View article: Data from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Data from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy Open
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet chemotherapy, with the recent a…
View article: Data from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Data from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy Open
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by early metastasis and extreme lethality. The backbone of SCLC treatment over the past several decades has been platinum-based doublet chemotherapy, with the recent a…
View article: Supplementary Data from Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models
Supplementary Data from Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models Open
This file contains additional details of the experimental methods that were used and briefly described in the main text. It also provides numerical values for the antibody uptake in various organs that have been presented as graphs in figu…
View article: Figures S1 - S5 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Figures S1 - S5 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy Open
Supplementary Figures
View article: Figures S1 - S5 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Figures S1 - S5 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy Open
Supplementary Figures
View article: Table S2 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy
Table S2 from Inhibition of XPO1 Sensitizes Small Cell Lung Cancer to First- and Second-Line Chemotherapy Open
Subtype information